This award recognises a public CEO that has demonstrated truly outstanding and exemplary leadership of a publicly-owned life science company. This category is a peer-to-peer award with votes having originated from the attending executives. As this is a joint award, there will be both an EU and US winner in this category.
At Intellia, we push the boundaries. We are focused on positively disrupting health care treatment of patients with genomic diseases. Conventional medicines treat the symptoms instead of the genetic cause of severe and life-threatening diseases, meaning that patients must take these therapies throughout their lives.
Intellia is revolutionizing medicine by harnessing the power of genome editing to develop potential cures. We bring new hope for people living with conditions including cancer, genetic disorders, viral infections, inflammatory disorders and many more.